Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 16091753)

1.

The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Schinnerl D, Fortschegger K, Kauer M, Marchante JR, Kofler R, Den Boer ML, Strehl S.

Blood. 2015 Feb 19;125(8):1282-91. doi: 10.1182/blood-2014-04-570960. Epub 2014 Dec 16.

2.

JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.

Jay J, Hammer A, Nestor-Kalinoski A, Diakonova M.

Mol Cell Biol. 2015 Jan;35(1):111-31. doi: 10.1128/MCB.01138-14. Epub 2014 Oct 20.

PMID:
25332239
3.

The molecular regulation of Janus kinase (JAK) activation.

Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN.

Biochem J. 2014 Aug 15;462(1):1-13. doi: 10.1042/BJ20140712. Review.

PMID:
25057888
4.

Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.

Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ.

Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.

PMID:
24909162
5.

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.

Furqan M, Mukhi N, Lee B, Liu D.

Biomark Res. 2013 Jan 16;1(1):5. doi: 10.1186/2050-7771-1-5.

6.

Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.

Anderson NM, Javadi M, Berndl E, Berberovic Z, Bailey ML, Huang K, Flenniken AM, Osborne LR, Adamson SL, Rossant J, Carter-Su C, Wang C, McNagny KM, Paulson RF, Minden MD, Stanford WL, Barber DL.

PLoS One. 2013 Sep 25;8(9):e75472. doi: 10.1371/journal.pone.0075472. eCollection 2013.

7.

JAK Kinases in Health and Disease: An Update.

Laurence A, Pesu M, Silvennoinen O, O'Shea J.

Open Rheumatol J. 2012;6:232-44. doi: 10.2174/1874312901206010232. Epub 2012 Sep 7.

8.

The centriolar satellite proteins Cep72 and Cep290 interact and are required for recruitment of BBS proteins to the cilium.

Stowe TR, Wilkinson CJ, Iqbal A, Stearns T.

Mol Biol Cell. 2012 Sep;23(17):3322-35. doi: 10.1091/mbc.E12-02-0134. Epub 2012 Jul 5.

9.

Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.

Onnebo SM, Rasighaemi P, Kumar J, Liongue C, Ward AC.

Haematologica. 2012 Dec;97(12):1895-903. doi: 10.3324/haematol.2012.064659. Epub 2012 Jun 24.

10.

Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Menicali E, Moretti S, Voce P, Romagnoli S, Avenia N, Puxeddu E.

Front Endocrinol (Lausanne). 2012 May 22;3:67. doi: 10.3389/fendo.2012.00067. eCollection 2012.

11.

JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.

Zouein FA, Duhé RJ, Booz GW.

Growth Factors. 2011 Dec;29(6):245-52. doi: 10.3109/08977194.2011.614949. Epub 2011 Sep 5. Review.

12.

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Jatiani SS, Baker SJ, Silverman LR, Reddy EP.

Genes Cancer. 2010 Oct;1(10):979-93. doi: 10.1177/1947601910397187.

13.

The use of structural biology in Janus kinase targeted drug discovery.

Alicea-Velázquez NL, Boggon TJ.

Curr Drug Targets. 2011 Apr;12(4):546-55. Review.

14.

Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Haan C, Behrmann I, Haan S.

J Cell Mol Med. 2010 Mar;14(3):504-27. doi: 10.1111/j.1582-4934.2010.01018.x. Epub 2010 Jan 28. Review.

15.

Janus kinases in immune cell signaling.

Ghoreschi K, Laurence A, O'Shea JJ.

Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Review.

16.

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Tefferi A.

J Cell Mol Med. 2009 Feb;13(2):215-37. doi: 10.1111/j.1582-4934.2008.00559.x. Epub 2008 Oct 23. Review.

17.

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Walz C, Cross NC, Van Etten RA, Reiter A.

Leukemia. 2008 Jul;22(7):1320-34. doi: 10.1038/leu.2008.133. Epub 2008 Jun 5.

18.

Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Kennedy JA, Barabé F, Patterson BJ, Bayani J, Squire JA, Barber DL, Dick JE.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16930-5. Epub 2006 Oct 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk